VIVUS Collaborates With Aetna to Test First Comprehensive Weight Management Program Integrating Weight Loss Medication

VIVUS Collaborates With Aetna to Test First Comprehensive Weight Management
Program Integrating Weight Loss Medication

New Program, Available Now, Integrates Qsymia to Help Bridge the Gap Between
Lifestyle Interventions and Surgical Treatments

MOUNTAIN VIEW, Calif., Jan. 14, 2014 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS), today announced that it has joined with Aetna (NYSE:AET), one
of the nation's leading diversified health care benefits companies, to
integrate Qsymia^® (phentermine and topiramate extended-release) capsules CIV
into a pilot program designed to evaluate the benefits of prescription
medication combined with lifestyle support for weight loss. The program is the
first of its kind involving Qsymia and a health care benefits provider.

"We are proud to partner with Aetna as they take the lead among payors in
developing a complete and integrated approach to chronic weight management,"
said Seth H. Z. Fischer, CEO of VIVUS. "Obesity is a serious disease, and we
believe patients need greater access to safe and effective options in order to
achieve the benefits of a lower, healthier weight."

The Aetna pilot program is currently being offered to self-insured plan
sponsors, and includes outreach to appropriate members and health care
providers regarding covered options. Participants in the pilot will also
receive free membership to Lose It!, a mobile app provided through Aetna
Navigator^® and CarePass^®, to support weight loss and positive lifestyle
changes.

"Aetna is committed to offering access to clinically proven options that may
deliver better results and hope for those struggling to lose weight," said Ed
Pezalla, MD, National Medical Director for Pharmacy Policy and Strategy,
Aetna. "Safety, effectiveness and value are our priorities. We want our
members to be informed about their options and give them the support they need
to make healthy changes."

"We are pleased to see pharmaceutical companies and payors collaborating to
address weight management in a comprehensive way to help solve the health
crisis and get more parties involved in the conversation," said Joe
Nadglowski, Obesity Action Coalition President and CEO. "We believe this
partnership will provide a successful model for future collaborations."

The pilot is expected to provide insight regarding impact on health outcomes,
workplace productivity and the potential for reductions in medical costs. The
program is projected to run through year-end 2014. Pilot participation is
being managed through Aetna. Eligible participants will receive information
through their employers.

About Qsymia

Qsymia is approved in the U.S. and is indicated as an adjunct to a
reduced-calorie diet and increased physical activity for chronic weight
management in adults with an initial body mass index (BMI) of 30 kg/m2 or
greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at
least one weight-related medical condition such as high blood pressure, type 2
diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health. For more information about the company,
please visit www.vivus.com.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995 and are
subject to risks, uncertainties and other factors, including risks and
uncertainties related to the impact on our business of the Aetna pilot program
offering comprehensive weight management; risks and uncertainties related to
the impact of the Aetna pilot program on weight management and the timing of
the program, including the insight provided by the program on the impact on
health outcomes, workplace productivity and the potential for reductions in
medical costs; risks and uncertainties related to the need for greater access
to safe and effective options to achieve the benefits of weight loss; and
risks and uncertainties related to collaborations between pharmaceutical
companies and payors providing a successful model for future collaborations.
These risks and uncertainties could cause actual results to differ materially
from those referred to in these forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. Investors should
read the risk factors set forth in VIVUS's Form 10-K for the year ending
December 31, 2012, as amended by the Form 10-K/A filed on April 30, 2013 and
by the Form 10-K/A filed on June 12, 2013, and periodic reports filed with the
Securities and Exchange Commission. VIVUS does not undertake an obligation to
update or revise any forward-looking statements.

CONTACT: VIVUS, Inc.
         Dana B. Shinbaum
         Corporate Development & Investor Relations
         shinbaum@vivus.com
        
         Media Relations: GolinHarris
         Ashley Buford
         abuford@golinharris.com
         212-373-6045
        
         Investor Relations: The Trout Group
         Brian Korb
         bkorb@troutgroup.com
         646-378-2923
 
Press spacebar to pause and continue. Press esc to stop.